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Astrocytes can be found between the vascular and neuronal elements of 
the central nervous system, where they take up and release molecules in order to 
maintain a homeostatic microenvironment for optimal neuron growth. 
Dysregulation of these astrocyte functions can lead to neuronal depolarization, 
hyperexcitability, excitotoxicity and subsequent neuronal death, characteristic of 
Amyotrophic Lateral Sclerosis (ALS). We hypothesize that the levels of 
glutamate and glutamate transporters in astrocytes increase over ALS disease 
progression and contribute to motor neuron death. Applying inclusion and 
exclusion criteria to a database comprising findings from over 2,000 papers 
resulted in data from over 60 papers. Data measuring glutamate concentrations 
and glutamate transmitter levels from SOD1 G93A (superoxide dismutase-1 
glycine 93 to alanine) transgenic ALS mouse models were normalized to wild-
type mice and graphed over time. We perform meta-analysis, correlation analysis, 
and survival analysis to determine the role of astrocytic glutamate regulation in 
disease progression. We demonstrate that GTL-1, GluR-1, and GluR-2 levels 
from astrocytes decrease over time. We propose that this trend may be associated 
with increased extracellular glutamate concentrations and the cellular attempts to 
maintain homeostasis. The findings of this analysis will give insight into the non-








 Astrocyte dysregulation has long been implicated in many motor neuron 
degenerative diseases. Astrocytes are the most abundant subtype of glial cells 
found in the central nervous system (CNS) and make up anywhere from 20-50% 
of brain volume (Rossi D., 2009). They can be found between the vascular and 
neuronal elements of the CNS which allows them to take up and release 
molecules in order to maintain a homeostatic microenvironment for optimal 
neuron growth (Kawamata et al., 2014). Astrocytes also absorb glucose from the 
blood and store it as glycogen, turn it into lactate through glycolysis (Rossi D., 
2009) or release it if glucose and oxygen supplies are low (Sofroniew & Vinters, 
2010). Furthermore, damage to the CNS results in a process known as astrogliosis 
(Cui et al., 2014). Astrocytes proliferate and migrate to the area of injury. They 
then surround the injured neurons and undergo cellular hypertrophy to form what 
is referred to as a glial scar. The glial scar restores blood brain barrier 
functionality, secludes the injury site, and releases neurotrophic factors to protect 
against apoptosis (Rossi D., 2009). However, astrocytes can also restrict axon 
regeneration and secrete neurotoxic and excitotoxic molecules such as pro-
inflammatory or cytotoxic cytokines (Fitch & Silver, 2008). Dysregulation of 
these astrocyte functions can lead to neuronal depolarization, hyperexcitability, 
excitotoxicity, and subsequent neuronal death, characteristic of Amyotrophic 
Lateral Sclerosis  
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(ALS) (Rossi D., 2009).   
A majority of ALS research has been focused on the role of astrocytes in 
the inflammatory response. It is not understood, however, if astrocyte 
dysregulation proceeds or is a product of the inflammatory response. Little is 
known about the temporal trends of glutamate excitotoxicity, metabolic 
homeostasis, and intracellular calcium signaling in disease progression (Li, 2015, 
Ngo, 2015, Kawamata, 2014). A study found there were no significant 
physiological benefits from increasing glutamate transporter 1 (GLT-1) levels in 
SOD1 mice, and it is believed that this is due to the occurrence of other critical 
pathophysiological events at the time of treatment (Li, 2015). An understanding 
of the changes in glutamate levels over disease progression is needed to support 
this hypothesis. Such research could help identify the optimal time for different 
types of treatment interventions.   
Using a database of over 2,000 papers, we propose to run meta-analysis 
and correlation analysis on data from papers measuring the concentrations of 
molecules involved in glutamate excitotoxicity, metabolic homeostasis, and 
intracellular calcium signaling in astrocytes from G93A SOD1 mice. Increased 
levels of glutamate and reduced levels of excitatory amino-acid transporter 2 
(EAAT2) have been found in the CNS of ALS patients, suggesting EAAT2 
dysfunction is involved in the disease progression (Li, 2015). The 
concentrations of glutamate, glutamate regulators, glutamate transporters, and 
glutamate receptors will be compared to determine the presence of significant 
temporal trends in disease progression. The findings of these analyses will give 
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Glutamate Excitotoxicity  
Astrocytes express glutamate transporters, GLT-1 in mice and EAAT2 in 
humans, which are responsible for most of the glutamate uptake in the CNS.  
Increased levels of glutamate and reduced levels of EAAT2 have been found in 
the CNS of ALS patients, suggesting EAAT2 dysfunction is involved in the 
disease progression (Li et al., 2015). The only FDA-approved treatment for ALS 
is an anti-glutamatergic compound called Riluzole but its benefits are mild and 
little is known about its mechanisms. Because of this, many studies have focused 
on finding ways to increase GLT-1 levels in astrocyte to increase glutamate 
reuptake. However, few have been successful. One such study (Li et al., 2015) 
used intraspinal injections of a GLT-1 vector in SOD1 G93A mice to study the 
physiological benefits of a potential gene delivery treatment. The reuptake of 
glutamate by astrocytes was measured, as well as motor neuron survival and in 
vivo information, such as hind limb strength and percent survival. The study 
found no physiological benefits from increasing intraspinal GLT-1 levels in 
SOD1 mice. It is believed that the main cause of the treatment failure was that the 
injections only began at 110 days of age, the age of  
ALS onset in SOD1 mice. If GLT-1 levels are becoming low at any point before 
onset, inducing GLT-1 treatment at onset may be too late effect a change in the 
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physiology. Additionally, GLT-1 is not the only component in the glutamate 
reuptake process. The benefits of a GLT-1 treatment could be optimized by an 
understanding of the temporal changes of glutamate and GLT-1 levels over the 
disease progression, as well as the interaction between other glutamate regulating 
molecules.   
One such molecule is small ubiquitin modifier 1- conjugated C-terminal 
fragment (CTE-SUMO1) which accumulates in spinal cord during disease 
progression (Foran, 2014). It was suspected that CTE-SUMO1 was affecting the 
localization of function of EAAT2 in astrocytes. Using primary astrocyte cultures 
of G93A mice, Foran et al. (2014) forced EAAT2 sumoylation in vitro. Increased 
intracellular clusters of EAAT2 and almost complete removal of EAAT2 from the 
plasma membrane were observed. This lead to reduced reuptake of extracellular 
glutamate. This study showed that, due to protein regulation within the cell, 
increasing EAAT2 levels doesn’t necessarily lead to the desired increases in 
glutamate reuptake, as observed in Li et al. (2015). Since the study was done in 
vitro, however, there is still a question of its efficacy. Localization in vitro can be 
very different than localization in vivo (Foran et al., 2014) and the results may not 
translate to in vivo disease progression. A broader, more comprehensive study of 
the interactions of all the components of glutamate regulation needs to be studied 
in vivo.   
Metabolic Homeostasis  
          ALS-causing genes are also linked to lipid homeostasis, glucose 
homeostasis, mitochondrial formation, ATP production, and other metabolic 
functions (Ngo and Steyn, 2015).  
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Extracellular concentrations of ATP in the CNS regulate activation and migration 
of immune and glial cells and increase in response to trauma and inflammation. 
These concentrations effect metabotropic (P2Y) and ionotropic (P2X) receptors 
in the nervous system. Activation of the P2X7 receptor, in particular, causes an 
increase in intracellular calcium (Gandelman et al., 2010). This activation, 
however, requires a 100 micromolar concentration of ATP and is believed to only 
arise under pathological conditions. In comparison, the P2X3 and P2X2/3 
receptors require only 1 micromolar of ATP for activation (Lewis et al., 1995). In 
astrocytes it can cause pro-inflammatory signaling which causes an increased 
production of nitric oxide and various chemokines (Gandelman et al., 2010). It 
has been found that G93A astrocytes degrade ATP at a faster rate than non-
transgenic astrocytes and display ATP-dependent proliferation. It has also been 
shown that high extracellular concentrations of ATP can cause non-transgenic 
astrocytes to induce motor neuron death (Gandelman et al., 2010). Mice with the 
SOD1 G93A mutation experience hypermetabolism and defects in glucose 
metabolism leading to significant weight loss. ALS metabolic dysfunction can 
have affects throughout the body and can be observed in the adipose, liver, and 
muscle tissues. Evidence shows that a complicated cycle of bioenergetic deficits 
may worsen disease progression over time (Ngo and Steyn, 2015). Ngo and Steyn 
(2015) studied the potential of potassium-ATP (K+-ATP) ion channels as a 
potential target for treatment of ALS. They specifically note the use of diazoxide, 
a small molecule that activates K+-ATP channels, in the treatment of other 
neurodegenerative diseases, such as Parkinson’s and Alzheimer’s. Similar to 
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glutamate, the temporal trends of metabolic homeostasis need to be determined in 
order to optimize treatments.   
Calcium Homeostasis  
A third non-inflammatory function of astrocytes is maintaining 
intracellular calcium (Ca2+) homeostasis. Intracellular Ca2+ plays a critical role in 
cell signaling and is tightly regulated in order to maintain homeostasis. Astrocytes 
are able to signal neurons by Ca2+ dependent release of glutamate (Rossi and 
Volterra, 2009). Intracellular concentrations of Ca2+ are characteristically elevated 
in response to pathological signaling. When the IP3 receptor is activated, Ca2+ is 
released from the endoplasmic reticulum (ER). The depletion of Ca2+ for the ER 
activates the store-operated calcium entry (SOCE) in order to maintain 
homeostatic conditions. However, oxidative stress can cause enhanced SOCE 
which leads to an overload of Ca2+ in the ER. This overload is closely associated 
to cell death pathways found in ALS progression (Kawamata and Manfredi, 
2010). The excitotoxic glutamate response of astrocytes relies on intracellular 
concentrations of Ca2+ but has also been found to be accompanied by the cytokine 
TNF-alpha. The blockage of the formation of TNF-alpha and ER Ca2+ overload 
have a significant negative effect on astrocyte glutamate release (Kawamata and 
Manfredi, 2010, Rossi and Volterra, 2009).  
Kawamata et al. (2014) found significantly increased levels of a modified 
protein involved in ER calcium release in ALS motor neuron cultures. This lead 
to significantly higher levels of intracellular calcium in the cultures. When they 
inhibited basal exocytosis in wildtype mice, however, there was no effect on 
 7 
motor neuron survival. This suggests there are factors at play other than just Ca2+ 
homeostasis dysregulation. They did not, however, look at end-stage neurons. 
Since the temporal trends of Ca2+ and glutamate regulation are not well 
understood there is a chance of delayed effects that can’t be seen until the end-
stage of the disease. Additionally, because glutamate, ATP, and Ca2+ homeostasis 
physiologically overlap, the changes in each should not be studied in isolation. 
All three categories should be studied over time in vivo to understand how the 
whole system interacts and changes throughout disease progression. Due to the 
large number of variables and the increased complications of in vivo studies, 
however, a single, all-encompassing experiment would not be feasible.  
Meta-Analysis  
The extent of research needed in this area naturally lends itself to a meta-
analysis. Meta-analysis uses a collection of data from a large number of published 
papers to study trends between studies rather than within a single study. In Irvin 
et al. (2015) they used meta-analysis to determine temporal trends in cellular 
respiration, oxidation, and calcium homeostasis in SOD1 G93A mouse models. 
They aggregated data from over 45 papers that met a specified set of 
inclusion/exclusion criteria and ran statistical analysis to find overarching trends 
spanning the whole life of a G93A mouse. The data included 15 different in vivo 
measures from four major categories; calcium regulation, mitochondrial 
mechanisms, cellular respiration, and oxidative regulation. They found that 
cellular respiration and corresponding ATP production is depressed starting from 
birth. Due to the nature of a meta-analysis study, however, there is a lot of 
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information and data excluded from the analysis. All the data must be aggregated 
in order to run statistical analysis. This requires combining data points from 
multiple different experiments. All the data points must fit a certain set of 
exclusion and inclusion principles in order to be included to ensure the quality of 
the statistical analysis. Because of this, many papers with useful data are not 
included. Much of ALS research is done in vitro using cell cultures as this is the 
faster and easier first step. However, this does not accurately reflect the disease 
onset and progression found in patients. Using meta-analysis allowed Irvin et al. 
(2015) to analyze data from the more accurate in vivo models in a shorter time 
frame.   
The current study will address the lack of understanding of the temporal 
changes in astrocyte regulation of glutamate homeostasis. It will also consider the 
in vivo relationships and interactions of regulating molecules in the categories. 
This will be done using meta-analysis of published papers from a database of over 
2,000 papers on ALS G93A mouse model research. Statistical analysis will be run 
to determine significant changes in the intracellular levels of glutamate and other 
molecules in astrocytes over disease progression. This research will help expand 
the body of knowledge on the mechanisms of ALS disease progression, 
specifically the non-inflammatory role of the astrocytes and will potentially 









Keyword Searches  
Keyword searches included a broad list of terms for each ALS subtopic 
explored. A list of these terms and which area they belonged to is found in Table 
1. These terms were used to identify articles with potential data points.  
Inclusion Exclusion Criteria  
Inclusion and exclusion criteria were created with the goal of limiting the 
number of papers to those with only useable data for analysis. Only data that met 
all the inclusion requirements and met none of the exclusion requirements was 
used. Studies using the transgenic SOD1 G93A mouse model to measure 
glutamate, glutamate transporters (GLT-1), glutamate receptors (GluR1 and 
GluR2), and intracellular calcium (Ca2+) in astrocytes were included in this study. 
Only data that was normalized to an age-matched wildtype (WT) mouse values or 
data that had corresponding age-matched WT mouse values that could be used for 
normalization were included. Any studies using low copy G93A mouse models 
were excluded. Low copy mice have longer lifespans and show symptom onset 
later than high copy mice. To accurately study changes over disease progression, 
only one copy number could be used. Low copy mice were excluded because 
they are the less common of the two models. A study was considered to use low 
copy mice if it was explicitly stated in the paper. Any data without identifiable 
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time points or cell extraction times, data without corresponding age-matched WT 
values, data from mice given a treatment, or data not from astrocytes was 
excluded in this study.   
Analysis of Data   
Quantified data was used to make ratios of SOD1 concentrations 
normalized to WT that were graphed over time. Measures of intracellular GTL-1, 
GluR1, GluR2, glutamate, and calcium were analyzed. The data points were 
aggregated into three disease stages; pre-onset (0-96 days), post-onset (97-116 
days), and end stage (117+ days). These brackets were determined by finding the 
average age of onset and age of death of the mice used in the studies (97 and 117 
days, respectively). Power analyses were performed on the data groups to 
determine minimum sample sizes needed to draw valid statistical conclusions. To 
reach an appropriate sample size, six data points were extrapolated from the post-
onset glutamate data. To determine statistical significance of protein levels 
between disease stages an ANOVA was run using the Bonferroni correction. To 
compare protein levels in G93A from WT a Student’s t-test was run at each 
disease stage.  
   
CHAPTER 4 
RESULTS 
A database of over 2,000 articles on ALS in the G93A SOD1 mouse 
model was narrowed down to 65 papers on glutamate regulation in astrocytes 
using keyword searches (Fig. 1). Applying the inclusion and exclusion criteria 
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resulted in 219 useable data points. Keyword searches were also used to identify 
77 and 75 papers for ATP and calcium data, respectively.  
There was no significant difference in glutamate or GluR2 concentrations 
in astrocytes over disease progression (Fig. 2 and 3). Glutamate and GluR2 
concentrations were also not significantly increased from WT concentrations at 
any disease stage. At end-stage, GLT-1 levels in astrocytes were significantly 
lower than end-stage WT values (p=0.036) and pre-onset G93A values 
(p=0.0061) (Fig.4). GluR1 concentrations in astrocytes were significantly 
decreased from post-onset levels (p=0.013) (Fig. 3). Intracellular calcium 
concentrations in G93A were significantly increased from WT at pre-onset (p=
0.0425) (Fig. 5). 
CHAPTER 5 
DISCUSSION 
Astrocytes do not Compensate for Increased Glutamate Levels 
It has been proposed that the hyperexcitability of motor neurons is caused 
by overstimulation by the main excitatory neurotransmitter, glutamate, which 
leads to a large influx of Ca2+ into the cell (Do-Ha, 2017). Motor neurons possess 
little ability to counteract the effects Ca2+ influx so overstimulation easily leads to 
excitotoxicity and cell death. Astrocytes play a critical role in reabsorbing excess 
extracellular glutamate and maintaining homeostasis for the motor neurons. This 
study found, however, that the concentrations of glutamate do not significantly 
increase in astrocytes over disease progression (Fig. 2). This suggests that the 
increased levels of glutamate found in the CNS of ALS patients are not being 
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reabsorbed by the astrocytes and are being left in the extracellular fluid to over 
stimulate the postsynaptic neurons.  
It is still unknown as to what causes the glutamate to collect within the 
CNS to begin with. One possible explanation is that, prior to onset of the disease, 
the astrocytes fail to reuptake the extracellular glutamate at the proper 
homeostatic rate. Another explanation is that the motor neurons, or some other 
cell, release glutamate at a significantly higher rate than normal. The astrocytes, 
however, continue to reabsorb at a normal rate which causes the glutamate to 
accumulate over time. Since the glutamate concentrations in the astrocytes are not 
significantly different from the levels found in WT (Fig. 2) at any time bin, it is 
likely that the astrocytes are not causing the initial problem. Why the astrocytes 
are not responding to the accumulation of glutamate is a point for further review. 
  
Astrocyte GLT-1 a Potential Target of ALS Treatment at End-stage  
Due to the moderate success of Riluzole, a compound that is thought to 
increase glutamate reuptake, there has been significant focus on finding ways to 
increase the reuptake of glutamate by astrocytes (Do-Ha, 2017). Additionally, 
post-mortem studies of ALS tissue and mice have found reduced levels of EAAT2 
and GLT-1, respectively (Rothstein, 1995, Pardo, 2006). It is believed that 
decreased GLT-1 levels are contributing to the accumulation of extracellular 
glutamate and increasing the levels could help prevent the hyperexcitability of the 
motor neurons. Few experiments have had any notable success, however, due to 
the complex interaction and timing of the pathophysiology (Li et al. 2015).  This 
study found that GLT-1 levels in astrocytes only decrease significantly from post-
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onset to end-stage (Fig. 4). This suggests that increasing astrocytic GLT-1 levels 
before end-stage may increase glutamate reuptake and prolong survival.  
  
Astrocyte GluR1 is a Potential Target for ALS Treatment at Pre-onset  
The influx of Ca2+ caused by the overstimulation of motor neurons leads to 
cell death as Ca2+ is involved in many apoptotic pathways. The permeability of 
glutamate receptors is determined by GluR subunits. Glutamate receptors with 
GluR1 subunits are highly permeable to Ca2+ and causes the mobilization of 
intracellular Ca2+ when activated (D’Antoni et al., 2011). GluR2 lacking 
glutamate receptors are highly permeable to Ca2+ (Grosskreutz, 2010). Studies 
have shown that a lack of GluR2 increased motor neuron degeneration (Van 
Damme et al., 2005) in mice and increasing GluR2 levels in motor neurons 
prolonged survival of mice (Tateno et al, 2004). While decreased GluR2 levels 
were not observed in ALS astrocytes in this study, there was a decrease in GluR1 
levels at end-stage when compared to pre-onset (Fig. 3). Intracellular Ca2+ levels 
also decreased from elevated levels at pre-onset to WT levels at end-stage. This 
suggests that reducing GluR1 levels in astrocytes at pre-onset could reduce 
intracellular Ca2+ levels and Ca2+ dysregulation effects. Additionally, GluR1 is 
elevated from WT at post-onset, though this difference wasn’t found to be 
significant. This lack of significance may be attributed to the small sample size of 
this time bin. Due to a limited number of data points quantified for intracellular 
Ca2+ that fell within the post-onset time bin this study was unable to examine the 
relationships of Ca2+ and the GluR subunits between 97 and 116 days.  
CHAPTER 6 
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CONCLUSIONS AND FUTURE WORK 
The purpose of this research was to help further understand the role of astrocytes 
and glutamate reuptake in the pathophysiology of ALS. Through meta-analysis it was 
found that intracellular glutamate does not change over time suggesting that the 
astrocytes are not responding to the increase in extracellular glutamate. GLT-1 levels 
were found to be decreased only at end-stage meaning GLT-1 treatments should be 
administered before 117 days of age in mice. Additionally, normal intracellular calcium 
levels correspond with decreased GluR1 levels. This indicates that lowering GluR1 levels 
in astrocytes could help improve calcium homeostasis and prolong cell survival. 
Altogether, this study finds that astrocyte function is failing to protect the motor neuron 
microenvironment in unexpected ways. Understanding these failings will help move ALS 
research closer to uncovering more effective treatments for the disease. 
 Moving forward, the role of astrocytes in calcium homeostasis will be examined 
with the same methods. The levels of various cytokines involved in the functions and 
uses of intracellular calcium will be compared across time bins to obtain a better 
understanding of why intracellular calcium levels are significantly increased at pre-onset. 
The hope for this research is to guide future studies towards more effective forms 
of ALS treatment. The lack of promising results from GLT-1 treatments in mice 
demonstrates this need. Timing of treatments is critical in clinical settings and these 
results suggest the GLT-1 treatments should be ministered prior to end-stage, whereas 
GluR treatments should begin as early as possible during pre-onset. The cross-talk 
between the glutamate excitotoxicity and calcium homeostasis pathways should also be 





FIGURES AND TABLES 
Table 1. Keywords for “Astrocytes” and terms associated with each subtopic.  
Subtopic  Terms  
Glutamate 
Excitotoxicity  
nitric oxide, NO* conc*, synt*, glutamate, glutamate* conc*, 
extracellular NO synt* conc, extracellular NO synt* level, 
GLT1 density in hippocampus, GLT1 density in striatum, GLT1 
density in M1Cx, GLT1 density in spinal cord, GLT1 density in 
S1Cx, GLT1* transporter*, GluRA, GluR1, GluR2, GluR3, 
GluR4  
The subtopics were broad topics that were used to categorize articles discussing 
ALS studies. The keywords were used in searches in the database to determine 
article numbers and potential data points for each subtopic.  
  





Figure 1. Inclusion and exclusion criteria. Inclusion/exclusion criteria were 
created with the goal of limiting the number of papers to those with only useable 
data for analysis.   
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Figure 2. Glutamate levels in astrocytes over ALS disease progression. 
Glutamate average ratios normalized to wild-type in three stages: 0-96 
days, 97-116 days, and 117+ days. There was no significant change in 
glutamate levels between any of the time bins.  
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Figure 3. GluR Complex levels in astrocytes over ALS disease progression. 
GluR1 and GluR2 average ratios normalized to wild-type in three stages: 
0-96 days, 97-116 days, and 117+ days. There was no significant change 
in GluR2 levels between time bins. GluR1 at 117+ days was significantly 
decreased from 97-116 (*p=0.013).  
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Figure 4. GLT-1 levels in astrocytes over ALS disease progression. GLT-1 
average ratios normalized to wild-type in three stages: 0-96 days, 97-116 
days, and 117+ days. GLT-1 is significantly decreased from 0-96 days 
(*p=0.036) and from WT (#p=0.0061) at 117+ days.  
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Figure 5.  Calcium levels in astrocytes over ALS disease progression.  
Intracellular Ca2+ average ratios normalized to wild-type in two stages: 0-
96 days and 117+ days.  Ca2+ at 0-96 days was significantly increased 
from WT (#p=0.0425) but not at 117+ days.  
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